Stifel raised the firm’s price target on Bio-Techne (TECH) to $65 from $60 and keeps a Hold rating on the shares. The company delivered a beat in fiscal Q2, but pull forward makes for flattish mid-year growth, resulting in a downward revision for next quarter and an unchanged outlook for the year, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target raised to $80 from $70 at TD Cowen
- Bio-Techne price target raised to $79 from $70 at UBS
- Bio-Techne price target raised to $70 from $61 at Baird
- Bio-Techne Earnings Call Balances Headwinds With Margin Gains
- Bio-Techne: Near-Term Resilience and Margin Expansion Support Accelerating Growth and Buy Rating Into 2027